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Introduction: Neoadjuvant chemotherapy followed by radical cystectomy (RC) and 
pelvic lymph node dissection (PLND) is the standard radical management for muscle-
invasive bladder cancer (MIBC). However, major pelvic surgery is not suitable for all 
patients and combined modality therapy (CMT) offers an alternative for patients who 
want to retain their bladder. Brachytherapy (BT) as part of CMT has been offered in 
selective cases of bladder cancer.  
Objectives: To evaluate the clinical effectiveness of BT for solitary urinary bladder 
tumours in terms of survival, local recurrence, and adverse events. 
Methods: A systematic review was conducted using defined search terms using online 
databases. Articles that discussed the use of BT as part of multi-modality treatments 
for MIBC were included.  
Results: Searches returned 112 articles of which 20 were deemed suitable for analysis. 
15 of the 20 articles reported overall survival (OS) at 5 years: 2747 patients were at 
risk and 1670 were alive after 5 years (60.7%): 7 studies reported OS at 10 years, with 
817 patients at risk and 350 alive after 10 years (42.85%). Disease specific survival 
(DSS) at 5 years was reported in 4 studies: 371 patients were at risk and 279 alive 
(75.2%) at 5 years. Local recurrence was reported across all 20 studies with an average 
rate of 14.8% (0-32%).  
Conclusion: There is low quality evidence to suggest that CMT with a BT boost is well 






Neoadjuvant chemotherapy followed by radical cystectomy (RC) and pelvic lymph 
node dissection (PLND) is the standard radical management for muscle invasive 
bladder cancer (MIBC) (1). Surgical techniques continue to advance, with robotic 
cystectomy (RARC) becoming increasingly popular. RARC results in less blood loss and 
a reduction in immediate post-surgical complications when compared to open 
retropubic surgery (2,3), however to date no longer term advantages have been 
demonstrated. 
 
However, major pelvic surgery is not suitable or acceptable for all patients. Bladder 
preservation using combined modality therapy (CMT): maximal transurethral 
resection of the bladder tumour, chemotherapy and radiotherapy, is an alternative for 
selected patients, with comparable outcomes to RC when salvage cystectomy is 
offered for muscle-invasive recurrence (4). CMT usually incorporates external beam 
radiotherapy (EBRT) without a brachytherapy (BT) boost. BT is well established 
technique for the treatment of certain cancers (e.g. adenocarcinoma of the prostate, 
and squamous cell carcinoma of the cervix), however its use to treat bladder cancers 
is not common practice. Bladder BT involves the delivery of high dose localised 
radiation using sealed radioactive sources passed either directly into the tumour, or 
through flexible catheters placed through and in close proximity to the tumour. 
Robotic-assisted laparoscopic brachytherapy (RALB) is a further refinement allowing 
the placement of these catheters using a minimally invasive technique (5). 
 
To date only one systematic review has attempted to compare the outcomes from RC 
and CMT with a brachytherapy boost (6). However, the authors concluded that due to 
the retrospective nature of the data analysed any differences in overall survival and 
cancer-specific survival were likely to reflect selection bias rather than a true 
treatment effect. 
 
Other reviews have been conducted analysing RC versus CMT without the use of BT 
(7,8). In a 2015 review by Arcangeli et al. CMT was not associated with a statistically 
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significant survival advantage (5-year OS: 57% v 52% p = 0.4). Similarly, in a 2018 
systematic review by Garcia-Perdomo et al. no difference in OS was found between 
CMT or RC (HR 1.06; 95%CI:0.85-1.31), however cancer-specific survival was better in 
the RC arm (HR:1.23 ;95%CI: 1.04-1.46) (7).  
 
The purpose of this systematic review is to assess available evidence on survival, 
recurrence rates and toxicity for patients who receive CMT that includes BT (CMT-BT) 
for MIBC and includes studies described in previous reviews in addition to those 




A systematic review was conducted using the Preferred reporting items of systematic 
reviews and meta-analysis (PRISMA) guidelines using predefined search terms (Figure 
1) (9) for ~ 50 days throughout January and February 2019. The detailed protocol for 
this systematic review is also registered on PROSPERO (CRD42019129349). The 
following databases were searched by two independent investigators (LM and CB): 
PubMed, OVID (Medline + EMBASE), Google Scholar, and conference sites (British Uro-
oncology Group/ESTRO). Hand searching and retrospective searching of relevant 
published literature was also undertaken.  
  
Search strategy  
The search terms were “brachytherapy OR interstitial radiotherapy AND urinary 
bladder cancer OR bladder tumour/cancer/neoplasm/muscle invasive bladder cancer 
AND survival*”. Abstracts and full manuscripts were individually read by two authors 
with any discordance mediated by a third member (MVH). Data on the treatment of 
MIBC with BT is primarily reported in retrospective studies. This is one of the 
justifications for conducting this review, as systematically reviewing these individual 
studies will provide missing information. A detailed description of the searches can be 




Rationale for inclusion and exclusion criteria  
Due to the relatively uncommon use of BT as a technique to treat MIBC, it was 
expected that many included studies would be retrospectives of small-medium cohort 
sizes, and to the best of our knowledge there has not been a randomised controlled 
trial looking at RC versus CMT (including BT). We included all studies that treated 
patients with tumours that had spread into the detrusor muscle and did not exclude 
the study if they also included patients with intermediate or high-grade non-muscle 
invasive bladder cancer (NMIBC). Publications were considered from anywhere in the 
world if the full text was available in English. To reduce bias, enhance credibility, and 
provide an accurate generalisation of the results, studies that followed up patients for 
at least 6 months were considered. No publication year limitation was set and all 
studies that met the inclusion criteria were considered. 
 
Study selection and data extraction  
Duplicates were removed and articles selected according to our inclusion criteria, 
irrelevant studies were removed based on title and abstract screening. After screening 
the titles and abstracts, full-text reports were assessed for eligibility. Any 
discrepancies were discussed with a third review author (MVH). The following data 
was extracted under the following headings: Authors and year of publication, type of 
study, country of origin, number of patients, BT technique + EQD2 (Gy), EBRT EQD2 
(Gy), stage, reported outcomes, median follow up (FU) (months), 5y OS (%), 5y DSS 
(%), and local recurrence rate (%). 
 
Risk of bias individual studies  
The Joanna Briggs Checklist for Quasi experimental non-randomised studies was used 
to critically analyse the risk of bias in each individual study and determine the quality 
of the studies available (10) (table 3).  
Sources of funding  
No funding was declared for included studies except for the large multi-centre 
retrospective by Koning et al. (11)  - they declared that their department received 






The summary measures were based on the 5y OS rates, 5y DSS rate, and local 
recurrence (%) of MIBC treated with CMT that included BT.  
 
 
Outcomes included in the study were: 
• 5-year survival defined as patients surviving 5 years or more after CMT-BT 
• DSS defined as % of people in the study who had not died from MIBC within a 
defined time period (2 or 5 years) 
• Disease recurrence outcomes defined as local recurrence of disease within 
the bladder either superficial, infiltrating or both after CMT-BT followed up 
for at least 6 months 
 
Analysis 
Statistical data and error reporting within included studies was not sufficiently 
homogenous, therefore a systematic narrative synthesis was undertaken instead of a 
meta-analysis according to Cochrane’s narrative synthesis guidelines (12). 
Results 
 
Identified studies and their characteristics 
112 articles were identified through database searches, after duplicates were 
removed 81 articles remained. A further 54 articles were removed after the 
inclusion/exclusion criteria were applied, reasons for exclusion can be found in figure 
1. Twenty-seven articles were deemed suitable for a full text read, with seven 
subsequently being excluded leaving 20 remaining articles for final analysis.  
 
In all studies patients had transurethral resection of their bladder tumours (TURBT) 
carried out to confirm histology, staging (presence of muscle invasion), and in some 
cases debulking of the tumour before EBRT. The decision as to whether the patient 
was suitable for BT was a joint decision between the urologist and radiation oncologist 
based on a post-TURBT cystoscopy. Partial cystectomies were carried out for select 
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cases, specifically for patients that had diverticular tumours (13–15), distal ureteric 
tumours (14,16) , or thick (1cm+) residual tumours located at the bladder dome 
(14,17). In one study, nine patients had partial cystectomies, as it was deemed 
necessary for the correct insertion of the catheters (18). Detailed study descriptions 
and results are contained in Table 1. 
 
The median age of a patient was 64.8 years (58.3-73): 80.8% (n = 2243) were male and 
19.2% (n = 532) female. All tumours were staged according to the Union for 
international cancer control cTNM method. The majority of tumours were within 
radical treatment intent range T1-T3, except for three studies which included patients 
with T4 tumours (11,16,19). These patients had previously received EBRT, which was 
unsuccessful, and were subsequently offered salvage BT for local control. All patients 
received EBRT before BT except for two studies. In one of these studies patients 
received BT as a monotherapy with or without adjuvant chemotherapy (20): and in 
the other, BT was delivered as a monotherapy, with EBRT or RC being offered if 
unsuccessful (21). BT was delivered via a range of techniques. Fifteen studies delivered 
BT to patients via low dose rate (LDR) or a combination of LDR and later pulsed dose 
rate (PDR) if the study included patients over many years (due to changes in 
technology). LDR brachytherapy (dose rate range 0.4-2Gy/h) was initially delivered 
using caesium-137 which was later replaced by iridium-192. PDR brachytherapy is 
radiobiologically comparable to LDR brachytherapy, however the treatment is 
delivered using a remote afterloading technique. The radiation is then delivered as 
short pulses over several hours. Two studies delivered pulsed high dose rate (10 x 
2.5Gy – 3# per day on consecutive days) BT via catheters implanted by RALB (5,14). 
 
Efficacy outcomes 
15 out of the 20 studies included in this review report OS outcomes at 5 years. 
Furthermore, other outcomes including disease-free survival and disease-specific 
survival were also reported (Table 1).  The median time to follow up was 40 months 
(range 12-196 months). Due to study heterogeneity 5-year OS ranges from 12-89% 
with a median of 60.7% of patients alive at 5 years (2747 patients in total and 1670 
alive at 5 years, Figure 2). Seven studies reported OS at 10 years (range 25-67%), with 
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817 patients at risk at the start and 350 alive after 10 years (42.8%). DSS was reported 
in five studies (range 70-82.8%), one of which reported 87% of patients were symptom 
and disease-free at two years (14).  Four studies reported that at five years a combined 
number of 371 patients were at risk and 279 alive (75.2%). Local recurrence (LR) was 
reported across all studies. The median LR rate was 14.8% (range 0-32%). Of note the 
study that reported a 0% LR rate was small (n = 16) and included only patients with 
recurrent tumours (20).   
 
Adverse events 
Acute and late adverse events (AE) were recorded across most studies except by Zhou 
et al. who reported no complications following brachytherapy. The most commonly 
used reporting system was the Radiation Therapy Oncology Group (RTOG), used by 
seven studies followed by the Common Terminology Criteria for Adverse Events 
(CTCAE), used for five (Table 4). AEs of any grade occurred in 491 (16.5%) patients with 
8.9% (267/2974) being in the acute phase (≤ 3 months) and 7.5% (224/2974) as late 
AEs. Acute side effects experienced by patients were largely confined to the bladder 
and included 36 patients (1.2%) with G3-4 urinary frequency and 10 (0.3%) with 
hydronephrosis. Significant late effects include bladder necrosis, reported in 164 
(5.8%) patients. Other common adverse effects included wound healing issues, urinary 




The main outcomes reported in studies investigating the efficacy of CMT-BT for MIBC 
were OS and DSS. When adjusted for stage, OS was consistent across the studies, 
however the studies that reported the highest OS (70-80%) included NMIBC in their 
results and had a small number of patients (18,22,23). The average DSS at 5 years was 
75.2%. There is no randomised data comparing RC and CMT-BT. As only a select 
patient population is suitable for the latter, any comparison would be associated with 
an inherent selection bias. For example, DSS post RC has been reported to range from 
52.3% to 58.9% (median follow-up ranging from 6.1-6.7 years), but these figures 
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reflect the inclusion of patients with tumours not amenable to CMT-BT (24). When 
adjusted for age, stage and grade, no statistically significant difference has been 
demonstrated for 5-year DSS between BT and RC (25). Bladder preservation with CMT 
alone is also an accepted management option for suitable patients, with overall 
survival and disease specific survival comparable to RC when salvage cystectomy is 
used for muscle invasive local recurrences (2). Based on this approach, bladder 
preservation with CMT-BT could also be considered with the option of a salvage 
cystectomy if required. The median LR rate across all of studies was 14.8%, some 
studies did report high local recurrences (> 30%) (21,26,27). In the study by Van der 
Steen-Banasik et al. (26) twenty-five local recurrences occurred within the bladder, 
thirteen of which had a salvage cystectomy. Two of the LR where non-infiltrating and 
were treated successfully with chemotherapy (Mitomycin C), and the other ten were 
inoperable due to metastasis. They also reported that nine (11.8%) were true implant 
recurrences where the BT boost was delivered. Similarly, in the Williams et al. (21) 
study eleven patients (7%) required a cystectomy due to local recurrences within the 
bladder. These higher percentages agree with studies that treated patients with CMT 
without brachytherapy.  A retrospective study (n = 155) that included patients treated 
with CMT from 2006-2012 reported a LR rate of 32.9% and a distant recurrence rate 
of 21% (28). In our study differences were observed in the reported results across 
several clinical variables – as discussed below. 
 
There was heterogeneity regarding eligibility criteria for CMT-BT within the cohort of 
studies analysed. However, for the majority the consensus was that the optimal 
patients had small (<5cm diameter), solitary, histologically proven transitional cell 
carcinoma with no evidence of concomitant carcinoma in situ. Tumour stage was an 
independent predictor for DSS in some studies. Van Onna et al. reported a hazard ratio 
19.8 (p = 0.01) for T3 versus T1 tumours (18). Van der steen-Banasik et al. reported a 
5y DDS of 80% for T1 and 60% for T2b (27).  Nieuwenhuijzen et al. reported that 
tumour stage and age showed an association with OS, but not with DSS (29). 
 
The majority of patients received a short course of EBRT before the BT boost, with the 
clinical target volume (CTV) being the whole bladder or the whole bladder + regional 
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lymph nodes. EBRT was deemed essential before the BT to lower the risk of graft 
metastases when surgically implanting the catheters, whilst also irradiating regional 
lymph nodes. Patients who did not have their nodes irradiated underwent dissection 
after EBRT. However, a study looking at bladder only versus whole pelvis 
chemoradiation reported no difference in 5y OS (52.9% vs 53% p = 0.8) or organ 
preservation (58.9% vs 57.1% p = 0.8) (29). In addition, the nodal doses delivered 
within the CMT-BT studies (20x2Gy/fraction and 3-4x3.5Gy/fraction) were lower than 
the standard doses used to treat microscopic nodal disease. In view of this the role of 
pelvic nodal irradiation is debatable. 
 
Differences in techniques to deliver BT also had an impact in the studies’ results. For 
instance, the study with the largest patient cohort, a multicentre retrospective (n = 
1040), reported a 5y OS rate of 62%, with a LR rate of 13%. The BT technique utilised 
had an impact on the success of the treatment, with PDR being superior to LDR for 
local control upon multivariate analysis (p = 0.0034), HDR was excluded due to small 
patient numbers. However, BT technique was deemed non-significant on  overall 
survival ( p = 0.53)   The increased clinical effectiveness of PDR compared to LDR-BT 
was thought to be due to advancements in 3D dose optimisation software and  the 
efficacy of PDR (11). Furthermore, the study by Aluwini et al. (15) included patients 
who had been treated prior to 1992 with LDR, and subsequent patients treated with 
PDR. They reported a LR rate of 22.2% in the LDR group and 19.6% in the PDR group 
(no statistically significant difference). Two studies used RALB to place the catheters 
instead of open surgery (5,30). Patients had a shorter mean duration of hospital stay 
and quicker recovery times compared to open catheter insertion. In the Bosschieter 
et al. the average hospitalisation stay time for RALB was five days whereas as other 
studies estimate the average hospitalisation stay for open surgery as 16 days (31).  
 
CMT-BT related adverse events were clinically acceptable. In the acute setting grade 
3-4 urinary symptoms (frequency, reflux, leakage) were the most common symptoms, 
along with delayed wound healing. The incidence of the latter declined as BT 
techniques evolved, and was uncommon after 1983 (19,27,32). Other AEs directly 
related to the BT catheters were rare.  However, in the study by Moonen et al. two 
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patients had their sigmoid colon perforated due to improper placement of the BT 
catheters, and death has also been reported due to surgical complications 
(2.2%)(16,21). In the studies with robust reporting of adverse events, the acute grade 
5 complication rate was 0.2%. This is comparable to the 90 day mortality rate post RC, 
although the patient populations will differ (2). 7.5% of patients experienced a late AE 
post CMT-BT; with most reported complications being grade 3-4 (only 0.2% of formally 
documented late complications were Grade 1-2). The most commonly reported late 
grade 3-4 AEs related to bladder necrosis (5.2%), but were usually asymptomatic 
findings at follow-up cystoscopy. Of note, none of the studies in this review assessed 
Patient Reported Outcome Measures (PROMS) or objective measures of long-term 
bladder function (urodynamics). 
 
None of the studies analysed in this review assessed patient quality of life (QOL) with 
validated tools. However, other studies have assessed QOL post-cystectomy and post 
bladder preservation with CMT alone. One study reported that potential changes in 
bowel habit and psycho-sexual health following RC were significant factors when 
deciding on treatment (33). Loss of sexual desire and orgasm disorders are frequently 
reported post cystectomy for women (34) whilst men may experience erectile 
dysfunction (35). In line with CMT alone, CMT-BT has the potential to offer selected 
patients with bladder cancer both curative treatment with a smaller detrimental long-
term impact on their psychosexual wellbeing (35).  
Conclusion 
 
Brachytherapy as part of CMT for MIBC is not a standard technique. Most 
retrospective studies have been confined to highly-specialised centres, largely located 
in the Netherlands. There is no randomised data available comparing the efficacy of 
CMT-BT, CMT alone, and RC, and all retrospective series are prone to selection bias. 
Our systematic review demonstrates that CMT-BT confers a 5-year DSS of 75%, and a 
5-year OS of 60%. It is an effective treatment in experienced centres for a selected 
patient population who wish to preserve their bladder. In such patients, CMT-BT is 
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Table 1: Included studies details and results 




































Solitary T1G3 or T2G1–3 UC of 5 






CFS at 1 + 
2y 
12 n/a n/a 3 (11%) 







The average size tumour treated 
was 9.3cm (3.5-21.2cm). All 
tumours were recurrences.  




OS, PFS at 
5y 
12 12 n/a 0 
Van der Steen-
Banasik et al. 
(14) 
2016 Retrospective Netherlands 70 57 (both) 
T2 solitary bladder tumour 
diameter 5 cm without carcinoma 












Aluwini et al. 
(15) 




Solitary, histologically proven MIBC 
(urothelial carcinoma) without 
clinical evidence of nodal or distant 
metastases. Exclusion criteria were 
CIS, tumour at the bladder neck or 
trigone, diameter of the (tumour) 
area to be treated >5 cm, and 
multifocal tumours. 
Interstitial (LDR 






105.5 65 n/a 40 (21%) 








Stage pT1–T3, cN0 or pN0, cM0, 
unifocal carcinoma and size ≤5 cm 
diameter. 
Interstitial (LDR, 






65 62 n/a 136 (13%) 
Van der Steen-










Solitary T1, Grade 3 or T2 tumours 
< 5 cm in patients fit for surgery 
















Netherlands 64 92/19 
Patients with a solitary T1G3–
T2Gall, tumour ≤5 cm 
without CIS or metastases, who 
were fit for surgery. 
Interstitial  (LDR 
or PDR): 52.5 
63 
OS, DSS, 















Stage pT1 (n = 30), pT2 (n =81) , 
and pT3 (n = 11) pN0 ( n=24)  pNx 
(n= 98). Transitional cell carcinoma 
n= 111 patients, adenocarcinoma 
(n = 6), other (n= 5). The tumour 
grade was Grade 1-2 (n= 16) , 
Grade 3 (n=103),  Grade 4 (n= 3).  
instillation n=12. 
Interstitial  (LDR 
or PDR): 60.51 
34.58 
LC, DRFS, 
RFS, OS 5, 
10y 
60 73 n/a 25 (20%) 
Nieuwenhuijzen 








Solitary lesion with a diameter of 
≤5 cm; clinical T1G3 and T2 stages; 
fit for surgery; and adequate 
bladder capacity (estimated 




















Superficial and infiltrating 
intravesical unifocal TCC less than 
5 cm in size, without iliac node 
involvement on intraoperative 
frozen section. A few patients with 
T3, node negative tumours who 
refused radical surgery were 
accepted for the protocol. 
Interstitial  
(LDR): 122.55 
10.37 LC, OS 5y 76 
pT1 
(89)                                  
pT2 














T2 tumours with poor degree of 
differentiation, vascular invasion, 
pathologic findings on intravenous 
pyelography, more than 1 
transurethral resection, and T3 
tumours (n = 8) T2G3 (n = 37), and 
T3a (n  = 4). 
Interstitial  (LDR 
and PDR): 46.33 













Solid tumour surface diameter of 






26 48 n/a 7 (11%) 







Unifocal tumours less than 5 cm 




LC, CSS, OS 
5y 
84 69 n/a 3 (3%) 
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(i) Solitary lesions with a 
diameter< 5 cm: (ii) high-grade T, 
stages and T2 T3 stages (muscle 
invasion but with no extension 
through the bladder wall): (iii) no 
history of cancer elsewhere in the 
bladder: (iv) fit for surgery: (v) 
adequate bladder capacity as 
estimated subjectively by the 
patients themselves. 
74 30 LC, OS 5y 40 86 n/a 2 (16%) 







Mean tumour size was 2.9 cm; 
pathological stages: pTis (n = 1); 
pT1, (n = 98), pT2 (n = 66), pT3a (n 
= 26); pT3b (n = 9), pT4 ( n = 1); 
unknown ( n = 4)  
Interstitial  
(LDR): 99.68 
15.68 OS 5y 51 62.3 n/a 35 (17%) 
Van der werf-









T2 or T3 growth with a diameter 
up to 5 cm 
Interstitial  
(LDR): 124.15 
40 OS 5y 
At least 
60 
80 n/a 6 (12.5%) 









Superficial and infiltrating unifocal 
bladder tumors ≤5 cm in diameter 
and technically amenable to partial 
cystectomy. All grades and 
histologies were accepted, but not 




15.41 DFS 5y 60 n/a n/a 13 (15%) 







(a) single lesions less than or equal 
to 5 cm; (b) no evidence or CIS on 
random bladder biopsies; (c) 
absence of grossly positive pelvic 
lymph nodes at the time of limited 
pelvic lymph node dissection; (d) 
absence of tumor invasion of 
structures other than prostate;  (e) 
medical operability: (f) no previous 




36.42 LC, OS 2y 22 n/a n/a 1 (7%) 
Van der werf-











Patients with a growth category 
T2, or T3, with a diameter not 
exceeding 5 cm 
Missing data 11.81 OS, 5, 10y 114 47.5 n/a 25 (6%) 









Patients with stage T1-T3. T1 (n = 




OS 5, 10y 
Missing 
data 
46 n/a 46 (31%) 
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Table 2: Reported acute and late adverse events related to combined modality therapy for bladder cancer* 
Adverse events (N = 2974) 
 
Patients n (%) 
  
Patients n (%) 
Acute any grade 267 (8.9) 
 
Late any grade  224 (7.5) 
Grade 1-2 43 (1.4) 
 
Grade 1-2 6 (0.2) 
Delay in wound healing  27 (0.9) 
 





Urethral pain requiring 
catheterisation 
1 (0.03) 
Wound infection 4 (0.1) 
 





Necrosis without complaints 
(bladder)  
156 (5.2) 
Urine retention 2 (0.06) 
 
Necrosis with complaints 
(bladder) 
18 (0.6) 




Telangiectasia 15 (0.5) 
Grade 3-4 216 (7.2) 
 
Urinary frequency  10 (0.3) 
Urinary frequency  40 (1.3) 
 
Recurrent cystitis  5 (0.1) 
Ureteric reflux 36 (1.2) 
 
Urethra stricture requiring 
surgery  
2 (0.06) 
Urinary leakage 27 (0.9) 
 
Hydronephrosis that required 
nephrectomy  
2 (0.06) 
Fistula 26 (0.8) 
 
Infection due to bladder 
necrosis after TURB 
1 (0.03) 
Wound healing problems  19 (0.6) 
 
Bladder necrosis that required 
partial cystectomy  
1 (0.03) 





Hydronephrosis 10 (0.3) 
 






Small bowel necrosis 1 (0.03) 
Necrosis (bladder) 7 (0.2) 
 







Small capacity bladder 
requiring palliative ileal 
conduit 
1 (0.03) 
Bowel complications 5 (0.1) 
 
Enterovesical fistula requiring 
urinary diversion and 
temporary ileostomy 
1 (0.03) 





Scar implant 3 (0.1) 
 
Urine leakage requiring 
catheter 
1 (0.03) 
Sigmoid perforation 3 (0.1) 
 
Grade 5 0 (0) 
Infection of the urinary 
tract 
2 (0.06) 




capacity of 150cc  
1 (0.03) 
   
Recurrent bladder calculi 
requiring cystectomy  
1 (0.03) 
   
Pyelonephritis secondary 
to ureteral stenosis  
1 (0.03) 
   
Stone formation 1 (0.03) 
   
Osteomyelitis 1 (0.03) 
   
Life-threatening 
pulmonary embolism  
1 (0.03) 
   
Pneumonia 1 (0.03) 
   
Grade 5 8 (0.2) 
   
Death due to surgical 
complications 
4 (0.1) 
   
Operative death 2 (0.06) 
   
Cardiac arrest 1 (0.03) 
   
Myocardial infarction 1 (0.03) 
   
 





Table 3: JBL appraisal checklist for included studies  
 
Study
1. Is it clear in the 
study what is the 
‘cause’ and what is the 
‘effect’ (i.e. there is 
no confusion about 
which variable comes 
first)?
2. Were the 
participants included 
in any comparisons 
similar? 
3. Were the 
participants included 
in any comparisons 
receiving similar 
treatment/care, other 
than the exposure or 
intervention of 
interest?
4. Was there a control 
group?
5. Were there 
multiple 
measurements of 
the outcome both 
pre and post the 
intervention/expo
sure?
6. Was follow up 
complete and if not, 
were differences 
between groups in 




7. Were the 
outcomes of 
participants 
included in any 
comparisons 
measured in the 
same way? 
8. Were outcomes 
measured in a reliable way?




Yes n/a n/a n/a Yes Yes n/a Yes Yes Include
DFS, LRFS, CFS 
reported using KP 
method
Zhou, 2017
Yes Yes Yes Yes Yes Yes n/a Yes Unclear Include
OS and PFS measured 
P values 
Mascarenhas, 2017
Yes n/a n/a n/a Yes Yes No Unclear Unclear Exclude
Single case study, no 
endpoints measured 
van der Steen-Banasik, 2016
Yes n/a n/a n/a Yes Yes No Yes Unclear Include
LC, OS, DFS,DSS 
reported
Aluwini, 2014
Yes n/a n/a n/a Yes Yes n/a Yes Unclear Include
OS, LRFS, CFS, SCFS, 
DMFS
Koning, 2011 Yes n/a n/a n/a Yes Yes n/a Yes Yes Include OS, DFS, LRFS, DMFS
van der Steen-Banasik, 2009Yes Yes Yes Yes Yes Yes Yes Yes Yes Include OS, DSS, CFS
van Onna, 2008 Yes No n/a n/a Yes Yes n/a Yes Yes Include OS, DFS, DSS
Blank, 2007 Yes n/a n/a n/a Yes Yes n/a Yes Yes Include LC, OS, DFS, LRFS, 
Nieuwenhuijzen, 2005 Yes Yes Yes Yes Yes Yes Yes Yes Yes Include OS, DSS
De Crevoisier, 2004 Yes n/a n/a n/a Yes Yes n/a Yes Yes Include LC, DSS
Soete, 1997
Yes n/a n/a n/a Yes No n/a Unclear No Exclude
No endpoints 
measured
van der Steen-Banasik, 2002Yes n/a n/a n/a Yes Yes n/a Yes Unclear Include LC
Wijnmaalen, 1997 Yes n/a n/a n/a Yes Yes n/a Yes Unclear Include OS, DFS, 
Pernot, 1996 Yes n/a n/a n/a Yes Yes n/a Yes Unclear Include LC, OS 
Moonen, 1994 Yes n/a n/a n/a Yes Yes n/a Yes Unclear Include LC, OS 
Rozan, 1992 Yes n/a n/a n/a Yes Yes n/a Yes Unclear Include OS
van der Werf-Messing, 
1989 
Yes n/a n/a n/a Yes Unclear n/a Yes Unclear Include
OS
Mazeron, 1988 Yes n/a n/a n/a Yes Yes n/a Yes Unclear Include DFS
Straus, 1988 Yes n/a n/a n/a Yes Yes n/a Yes Unclear Include LC, OS
van der Werf-Messing, 
1983
Yes n/a n/a n/a Yes Yes n/a Yes Unclear Include
OS




Table 4: Further detail on adverse events 








Acute < 3 months Late > 3 months 
Bosschieter et 
al. (5)  
23 7 
(30.4)  
Clavien-Dindo Non-specific grade 1 (4) 
Accidentally removed BTC 
necessitating RAL 
repositioning (1) 






Zhou et al. (20)  16 0 
(0.0) 
   
Van der Steen-
Banasik et al. 
(14) 




pulmonary embolism (1) 
Myocardial infarction (1) 
Infection due to bladder 
necrosis after TURB (1) 
Recurrent cystitis requiring 
hospitalization (1) 









Treatment of Cancer 
(RTOG/EORTC) 
grading system 
Wound healing (10) Necrosis with complaints (12) 




Multiple  Necrosis (144) 
Fistula (24) 
Van der Steen-







Wound infections (6) 
Temporary psychotic (2) 
Urinary leakage (2) 
Ileus (1) 
Pneumonia (1) 
Cardiac failure (1)  
 
Urine leakage (3) 
Fistula (5) 









Postoperative ileus (4) 
 





Reduced bladder capacity (3) 
Nieuwenhuijzen 








Treatment of Cancer 
(RTOG/EORTC) 
grading system 
 Persisting vesicocutaneous 
fistula (1) 
Stricture of the urethra and 
ureters (1) 







Urinary frequency (16) 
Macroscopic haematuria 
(2) 
Infection of the proximal 
urinary tract (2) 
 
Urinary frequency (10) 
Bladder calcification (1 
patient) 
Ureteral stenosis requiring 
double-J stent (1) Small bowel 
necrosis (1) 
Van der steen-









Treatment of Cancer 
(RTOG/EORTC) 
grading system 
Wound infection (4) 
Urine retention (2) 
Temporary psychotic  (2) 
Bladder bleeding 

















Treatment of Cancer 
(RTOG/EORTC) 
grading system 
Frequency in urination 
(9) 





Necrosis without complaints 
(9) 
Necrosis with complaints (2) 
 









Treatment of Cancer 
(RTOG/EORTC) 
grading system 
Delay in wound healing 
(27) 
Severe radiation cystitis (3) 
Hydronephrosis that required 
nephrectomy (2) 









Treatment of Cancer 
(RTOG/EORTC) 
grading system 
Wound infections (3) 
Urinary leakage (3) 
Psychological problems 
(3)  
Sigmoid perforation (1)  
Osteomyelitis (1) 
Haematoma (1) 
Accidental perforation of 
the sigmoid colon due to 
improper placement of 
catheters (2) 
 
Rozan et al. (16)  205 13 
(6.3) 
Not stated Urinary leak (5) 
Death due to surgical 
complications (3)   
Stenosis requiring surgery (1) 
Necrosis required partial 
cystectomy (1) 
Urinary diversion and 
temporary ileostomy for an 
entero-vesical fistula (1) 
Chronic cystitis and 
haematuria (1) 
Ureteral implantation due to 
pyelonephritis (1) 
Van der werf-








Death due to surgical 
complication (1)  
Stone formation (1) 
Bowel complications (1)  
 
 




Not stated Urinary leakage (5) Chronic cystitis (1)  
Pyelonephritis secondary to 
ureteral stenosis (1) 













cystitis (3)  
Decreased bladder 
capacity of 150cc (1) 
Recurrent bladder calculi 
requiring cystectomy (1)  
Moderate scrotal and 
penile oedema (1) 
 
Van der werf-




Not stated  Necrosis without 
symptoms (62) 
Stone formation (29) 
Necrosis with symptoms (4) 
Bladder cystitis (1) 




Not stated  Ureteric reflux (36) 
Suprapubic urinary leak 
(12) 
Scar implant (3) 






Figure 1: Preferred reporting items for systematic reviews and meta-analysis (PRISMA) flow diagram of included 








































Bladder cancer treated with CMT-BT




Please find detailed information as to how we carried out our searching and sifting 
process.  
 
Figure 1: PubMed search details 
 
 
Figure 2: Ovid search details 
• AMED (Allied and Complementary Medicine) 1985 to May 2019* 
•  CityLibrary Journals@Ovid 
• EBM Reviews - ACP Journal Club 1991 to April 2019 
• EBM Reviews - Cochrane Central Register of Controlled Trials March 2019 
•  EBM Reviews - Cochrane Database of Systematic Reviews 2005 to April 24, 2019 
• EBM Reviews - Cochrane Methodology Register 3rd Quarter 2012  
•  EBM Reviews - Database of Abstracts of Reviews of Effects 1st Quarter 2016 
•  EBM Reviews - Cochrane Clinical Answers April 2019 
•  EBM Reviews - Health Technology Assessment 4th Quarter 2016 
•  EBM Reviews - NHS Economic Evaluation Database 1st Quarter 2016 
•  Embase 1974 to 2019 Week 17  
•  Global Health 1973 to 2019 Week 16 
•  HMIC Health Management Information Consortium 1979 to January 2019 
•  Journals from Ovid 
•  Maternity & Infant Care Database (MIDIRS) 1971 to March 2019 
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•  Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations 
and Daily 1946 to April 30, 2019 
•  Social Policy and Practice 201904 
•  Ovid Nursing Database 1946 to April Week 3 2019 
*Included databases in the OVID search  
 
List of excluded studies 
1: Saltzman AF, Cost NG. Current Treatment of Pediatric Bladder and Prostate 
Rhabdomyosarcoma. Curr Urol Rep. 2018 Feb 22;19(1):11. doi: 
10.1007/s11934-018-0761-8. Review. PubMed PMID: 29468476. SARCOMA 
2: Mascarenhas F, Maes K, Marques F, Formoso R, Antunes T. Robot-assisted 
brachytherapy of the bladder with long distance support using video conferencing. 
J Contemp Brachytherapy. 2017 Aug;9(4):375-382. doi: 10.5114/jcb.2017.69548. 
Epub 
2017 Aug 30. PubMed PMID: 28951758; PubMed Central PMCID: PMC5611459. 
SURVIVAL NOT MEASURED 
3: Cosset JM, Belin L, Wakil G, Flam T, Thiounn N, Pierrat N, Pontvert D, 
Savignoni A, Chauveinc L. Second malignancies after permanent implant prostate 
cancer brachytherapy: A single-institution study of 675 patients treated between  
1999 and 2003. Cancer Radiother. 2017 May;21(3):210-215. doi: 
10.1016/j.canrad.2017.02.003. Epub 2017 May 9. PubMed PMID: 
28499661.PROSTATE 
4: Chargari C, Haie-Meder C, Guérin F, Minard-Colin V, de Lambert G, Mazeron R, 
Escande A, Marsolat F, Dumas I, Deutsch E, Valteau-Couanet D, Audry G, Oberlin O, 
Martelli H. Brachytherapy Combined With Surgery for Conservative Treatment of 
Children With Bladder Neck and/or Prostate Rhabdomyosarcoma. Int J Radiat Oncol 
Biol Phys. 2017 Jun 1;98(2):352-359. doi: 10.1016/j.ijrobp.2017.02.026. Epub 2017 
Feb 21. PubMed PMID: 28463154. SARCOMA 
5: Fietkau R. [When is a nonsurgical approach possible for metastatic primary 
tumors and lymph node metastases of the urinary bladder and prostate?]. Urologe 
A. 2017 May;56(5):570-578. doi: 10.1007/s00120-017-0379-3. Review. German. 
PubMed 
PMID: 28424830. PROSTATE 
6: Haidl F, Pfister D, Semrau R, Heidenreich A. [Second neoplasms after 
percutaneous radiotherapy]. Urologe A. 2017 Mar;56(3):342-350. doi: 
10.1007/s00120-016-0277-0. Review. German. PubMed PMID: 27844130. REVIEW 
7: Seitz G, Fuchs J, Sparber-Sauer M, Leuschner I, Godzinski J, Klingebiel T, 
Schuck A, Martus P, Dantonello TM, Koscielniak E. Improvements in the Treatment 
of Patients Suffering from Bladder-Prostate Rhabdomyosarcoma: A Report from the 
CWS-2002P Trial. Ann Surg Oncol. 2016 Nov;23(12):4067-4072. Epub 2016 Jul 7. 
PubMed PMID: 27387676. SARCOMA 
8: Martelli H, Borrego P, Guérin F, Boubnova J, Minard-Colin V, Dumas I, Chargari 
C, Haie-Meder C. Quality of life and functional outcome of male patients with 
bladder-prostate rhabdomyosarcoma treated with conservative surgery and 
brachytherapy during childhood. Brachytherapy. 2016 May-Jun;15(3):306-311. doi: 
28 
 
10.1016/j.brachy.2016.01.001. Epub 2016 Feb 16. PubMed PMID: 26895712. 
SARCOMA 
9: Luchey AM, Lin HY, Yue B, Agarwal G, Gilbert SM, Lockhart J, Poch MA, Pow-Sang 
JM, Spiess PE, Sexton WJ. Implications of Definitive Prostate Cancer Therapy on 
Soft Tissue Margins and Survival in Patients Undergoing Radical Cystectomy for 
Bladder Urothelial Cancer. J Urol. 2015 Nov;194(5):1220-5. doi: PROSTATE 
10.1016/j.juro.2015.05.091. Epub 2015 Jun 6. PubMed PMID: 26055823. 
10: Bos MK, Marmolejo RO, Rasch CR, Pieters BR. Bladder preservation with 
brachytherapy compared to cystectomy for T1-T3 muscle-invasive bladder cancer: a  
systematic review. J Contemp Brachytherapy. 2014 Jun;6(2):191-9. doi: 
10.5114/jcb.2014.43777. Epub 2014 Jun 28. Review. PubMed PMID: 25097561; 
PubMed 
Central PMCID: PMC4105649. REVIEW 
11: Goossens-Laan CA, Leliveld AM, Verhoeven RH, Kil PJ, de Bock GH, Hulshof MC,  
de Jong IJ, Coebergh JW. Effects of age and comorbidity on treatment and survival 
of patients with muscle-invasive bladder cancer. Int J Cancer. 2014 Aug 
15;135(4):905-12. doi: 10.1002/ijc.28716. Epub 2014 Jan 25. PubMed PMID: 
24420527. NO BRACHY 
12: Haie-Meder C, Mazeron R, Martelli H, Oberlin O. [Brachytherapy role in 
pediatric rhabdomyosarcomas]. Cancer Radiother. 2013 Apr;17(2):155-8. doi: 
10.1016/j.canrad.2012.12.011. Epub 2013 Feb 8. Review. French. PubMed PMID: 
23683937. SARCOMA 
13: Hulshof MC, Pieters BR, Koning CC. [Bladder-conserving treatment for bladder  
cancer: potential of and developments in radiotherapy]. Ned Tijdschr Geneeskd. 
2013;157(19):A5556. Review. Dutch. PubMed PMID: 23657098. REVIEW 
14: Goossens-Laan CA, Visser O, Hulshof MC, Wouters MW, Bosch JL, Coebergh JW, 
Kil PJ. Survival after treatment for carcinoma invading bladder muscle: a Dutch 
population-based study on the impact of hospital volume. BJU Int. 2012 
Jul;110(2):226-32. doi: 10.1111/j.1464-410X.2011.10694.x. Epub 2011 Nov 1. 
PubMed 
PMID: 22044615. NO BRACHY 
15: Heinzelmann F, Thorwarth D, Lamprecht U, Kaulich TW, Fuchs J, Seitz G, 
Ebinger M, Handgretinger R, Bamberg M, Weinmann M. Comparison of different 
adjuvant radiotherapy approaches in childhood bladder/prostate 
rhabdomyosarcoma 
treated with conservative surgery. Strahlenther Onkol. 2011 Nov;187(11):715-21. 
doi: 10.1007/s00066-011-2261-3. Epub 2011 Oct 29. PubMed PMID: 22037652. 
SARCOMA 
16: Das D, Chaudhuri S, Deb AR, Aich RK, Gangopadhyay S, Ray A. Treatment of 
cervical carcinoma with high-dose rate intracavitary brachytherapy: two years 
follow-up study. Asian Pac J Cancer Prev. 2011;12(3):807-10. PubMed PMID: 
21627388. CERVIX 
17: Pouessel D, Thariat J, Lagrange JL, Mottet N, Culine S. [Perioperative 
strategies in patients with muscle invasive bladder cancer]. Bull Cancer. 2010;97 
Suppl Cancer de la vessie:5-9. doi: 10.1684/bdc.2010.1096. French. PubMed PMID: 
20534384. FULL TEXT NOT IN ENGLISH 
18: Jayram G, Katz MH, Steinberg GD. Radical cystectomy in patients previously 
29 
 
treated for localized prostate cancer. Urology. 2010 Dec;76(6):1430-3. doi: 
10.1016/j.urology.2010.01.048. Epub 2010 Apr 8. PubMed PMID: 20381130. 
PROSTATE 
19: Yee DS, Shariat SF, Lowrance WT, Sterbis JR, Vora KC, Bochner BH, Donat SM, 
Herr HW, Dalbagni G, Sandhu JS. Impact of previous radiotherapy for prostate 
cancer on clinical outcomes of patients with bladder cancer. J Urol. 2010 
May;183(5):1751-6. doi: 10.1016/j.juro.2010.01.014. Epub 2010 Mar 17. PubMed 
PMID: 20299035; PubMed Central PMCID: PMC4295901. PROSTATE 
20: Bevers RF, Battermann JJ, Gietema JA, Hulsbergen-Van de Kaa CA, de Reijke TM, 
Feller N, Witjes JA; De Nederlandse Vereniging voor Urologie; Vereniging van 
Integrale Kankercentra (VIKC). [Guideline on urothelial carcinoma of the 
bladder]. Ned Tijdschr Geneeskd. 2009;153:A956. Dutch. PubMed PMID: 20051162 
OPINION. 
21: Brown AP, Neeley ES, Werner T, Soisson AP, Burt RW, Gaffney DK. A 
population-based study of subsequent primary malignancies after endometrial 
cancer: genetic, environmental, and treatment-related associations. Int J Radiat  
Oncol Biol Phys. 2010 Sep 1;78(1):127-35. doi: 10.1016/j.ijrobp.2009.07.1692. 
Epub 2009 Nov 10. PubMed PMID: 19910129. CERVIX/GYNAE 
22: Sandhu A, Mundt AJ. Radiation therapy for urologic malignancies in the 
elderly. Urol Oncol. 2009 Nov-Dec;27(6):643-52. doi: 
10.1016/j.urolonc.2009.07.019. PubMed PMID: 19879475. OPINION 
23: Lee DJ, Rothberg MB, McKiernan JM, Benson MC, Badani KK. Robot-assisted 
radical cystoprostatectomy in complex surgical patients: single institution 
report. Can J Urol. 2009 Jun;16(3):4664-9. PubMed PMID: 19497175. NO BRACHY 
24: Thariat J, Caullery M, Ginot A, Hannoun-Lévi JM, Barrière J, Buthaud X, 
Marcié S, Bondiau PY, Housset M, Lagrange JL, Amiel J, Gérard JP. [State of the 
art and advances in radiotherapy for bladder cancer]. Prog Urol. 2009 
Feb;19(2):85-93. doi: 10.1016/j.purol.2008.11.002. Epub 2008 Dec 16. French. 
PubMed PMID: 19168010. REVIEW 
25: Martelli H, Haie-Meder C, Branchereau S, Franchi-Abella S, Ghigna MR, Dumas 
I, Bouvet N, Oberlin O. Conservative surgery plus brachytherapy treatment for 
boys with prostate and/or bladder neck rhabdomyosarcoma: a single team 
experience. J Pediatr Surg. 2009 Jan;44(1):190-6. doi: SARCOMA/PROSTATE 
10.1016/j.jpedsurg.2008.10.040. PubMed PMID: 19159742. 
26: Da Pozzo L. Editorial comment on: External beam radiation therapy followed by 
interstitial radiotherapy with iridium-192 for solitary bladder tumours: results  
of 111 treated patients. Eur Urol. 2009 Jul;56(1):122. doi:  
10.1016/j.eururo.2008.07.045. Epub 2008 Aug 21. PubMed PMID: 18722047. 
COMMENT 
27: Herr HW. Editorial comment on: External beam radiation therapy followed by 
interstitial radiotherapy with iridium-192 for solitary bladder tumours: results  
of 111 treated patients. Eur Urol. 2009 Jul;56(1):121. doi: 
10.1016/j.eururo.2008.07.044. Epub 2008 Aug 21. PubMed PMID: 18722045. 
OPINION/DUPLICATE 
28: Pansadoro V, Emiliozzi P. Bladder-sparing therapy for muscle-infiltrating 
bladder cancer. Nat Clin Pract Urol. 2008 Jul;5(7):368-75. doi: 
10.1038/ncpuro1145. Epub 2008 Jun 17. Review. PubMed PMID: 18560383. REVIEW 
30 
 
29: Kaouk JH, Hafron J, Goel R, Haber GP, Jones JS. Robotic salvage retropubic 
prostatectomy after radiation/brachytherapy: initial results. BJU Int. 2008 
Jul;102(1):93-6. doi: 10.1111/j.1464-410X.2008.07570.x. Epub 2008 Apr 11. PubMed  
PMID: 18410443. PROSTATE 
30: Kerst JM, Pos FJ, Visser O, Horenblas S. [New developments in the treatment 
of muscle-invasive bladder cancer]. Ned Tijdschr Geneeskd. 2008 Jan 
26;152(4):187-92. Review. Dutch. PubMed PMID: 18320942. REVIEW 
31: Jordana F, Lagrange JL, Gérard JP, Amiel J. [Role of the combination of 
external radiotherapy--partial cystectomy--interstitial brachytherapy in pT1 G3,  
pT2 and pT3 bladder tumors]. Ann Urol (Paris). 2005 Nov;39 Suppl 5:S104-12. 
Review. French. PubMed PMID: 16425727. REVIEW 
32: Pos F, Horenblas S, Dom P, Moonen L, Bartelink H. Organ preservation in 
invasive bladder cancer: brachytherapy, an alternative to cystectomy and combined 
modality treatment? Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):678-86. PubMed 
PMID: 15708245. REVIEW 
33: Pos F, Moonen L. Brachytherapy in the treatment of invasive bladder cancer. 
Semin Radiat Oncol. 2005 Jan;15(1):49-54. Review. PubMed PMID: 15662607. 
REVIEW 
34: Viegas CM, Araujo CM, Dantas MA, Froimtchuk M, Oliveira JA, Marchiori E, 
Souhami L. Concurrent chemotherapy and hypofractionated twice-daily radiotherapy  
in cervical cancer patients with stage IIIB disease and bilateral parametrial 
involvement: a phase I-II study. Int J Radiat Oncol Biol Phys. 2004 Nov 
15;60(4):1154-9. PubMed PMID: 15519787. CERVIX 
35: Nieuwenhuijzen JA, Horenblas S, Meinhardt W, van Tinteren H, Moonen LM. 
Salvage cystectomy after failure of interstitial radiotherapy and external beam 
radiotherapy for bladder cancer. BJU Int. 2004 Oct;94(6):793-7. PubMed PMID: 
15476510. NO BRACHY 
36: Greven K, Winter K, Underhill K, Fontenesci J, Cooper J, Burke T; Radiation 
Therapy Oncology Group. Preliminary analysis of RTOG 9708: Adjuvant postoperative 
radiotherapy combined with cisplatin/paclitaxel chemotherapy after surgery for 
patients with high-risk endometrial cancer. Int J Radiat Oncol Biol Phys. 2004 
May 1;59(1):168-73. PubMed PMID: 15093913. CERVIX 
37: Widmark A, Flodgren P, Damber JE, Hellsten S, Cavallin-Ståhl E. A systematic  
overview of radiation therapy effects in urinary bladder cancer. Acta Oncol. 
2003;42(5-6):567-81. Review. PubMed PMID: 14596515. REVIEW 
38: Dunst J, Rödel C, Diestelhorst A, Heynemann H, Schrott KM, Sauer R. 
Radiochemotherapy for T1G3 bladder cancer. Front Radiat Ther Oncol. 
2002;36:151-8. Review. PubMed PMID: 11842745. REVIEW 
39: Pedraza V, Cueto J, Castillo I, Gonzalo C, Romero MJ, Zuluaga A. [Critical 
vision in the treatment of invasive vesical cancer with ionizing radiation]. Arch 
Esp Urol. 1999 Jul-Aug;52(6):662-74. Review. Spanish. PubMed PMID: 10484850. 
REVIEW 
40: González González D, Haitze van der Veen J, Ypma AF, Blank LE, Hoestra CJ, 
Veen RE. [Brachytherapy for urinary bladder cancer]. Arch Esp Urol. 1999 
Jul-Aug;52(6):655-61. Review. Spanish. PubMed PMID: 10484849. REVIEW 
41: Movsas B, Chapman JD, Horwitz EM, Pinover WH, Greenberg RE, Hanlon AL, Iyer 
R, Hanks GE. Hypoxic regions exist in human prostate carcinoma. Urology. 1999 
31 
 
Jan;53(1):11-8. PubMed PMID: 9886581. PROSTATE 
42: Hoffstetter S, Hubert J, Guillemin F, Peiffert D, Marchal C, Luporsi E, 
Pernot M. [Interstitial brachytherapy in infiltrating cancer of the bladder. The  
Nancy experience]. Cancer Radiother. 1998 Apr;2 Suppl 1:54s-61s. French. PubMed 
PMID: 9749080. FULL TEXT NOT IN ENGLISH  
43: Zietman AL, Shipley WU, Heney NM, Althausen AF. The case for radiotherapy 
with or without chemotherapy in high-risk superficial and muscle-invading bladder 
cancer. Semin Urol Oncol. 1997 Aug;15(3):161-8. Review. PubMed PMID: 9394911. 
REVIEW 
44: Vogt HG, Martin T, Kolotas C, Schneider L, Strassmann G, Zamboglou N. 
Simultaneous paclitaxel and radiotherapy: initial clinical experience in lung 
cancer and other malignancies. Semin Oncol. 1997 Aug;24(4 Suppl 
12):S12-101-S12-105. Review. PubMed PMID: 9331131. LUNG 
45: Durdux C, Housset M. [Radiotherapy and chemotherapy in infiltrating bladder 
tumors]. Rev Prat. 1997 Feb 15;47(4):392-5. Review. French. PubMed PMID: 
9114525. REVIEW 
46: Colvett KT, Althausen AF, Bassil B, Heney NM, McGovern FV, Young HH 2nd, 
Kaufman DS, Zietman AL, Shipley WU. Opportunities with combined modality 
therapy  
for selective organ preservation in muscle-invasive bladder cancer. J Surg Oncol. 
1996 Nov;63(3):201-8. Review. PubMed PMID: 8944067. REVIEW 
47: Lybeert ML, Ribot JG, de Neve W, Goor C, Crommelin MA. Carcinoma of the 
urinary bladder: long-term results of interstitial radiotherapy. Bull Cancer 
Radiother. 1994;81(1):33-40. PubMed PMID: 7893521. 
48: Skladowski K, McMillan TJ, Peacock J, Titley J, Steel GG. Cell-cycle 
progression during continuous low dose rate irradiation of a human bladder 
carcinoma cell line. Radiother Oncol. 1993 Sep;28(3):219-27. PubMed PMID: 
8255999.NO BRACHY  
49: De Neve W, Lybeert ML, Goor C, Crommelin MA, Ribot JG. T1 and T2 carcinoma 
of 
the urinary bladder: long term results with external, preoperative, or 
interstitial radiotherapy. Int J Radiat Oncol Biol Phys. 1992;23(2):299-304. 
PubMed PMID: 1587750. FULL TEXT NOT AVAIABLE  
50: Porter AT. The role of radiotherapy in the treatment of muscle invasive 
bladder cancer. Prog Clin Biol Res. 1990;353:23-34. Review. PubMed PMID: 2217424. 
REVIEW 
51: Cox JD, Guse C, Asbell S, Rubin P, Sause WT. Tolerance of pelvic normal 
tissues to hyperfractionated radiation therapy: results of Protocol 83-08 of the  
Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1988 
Dec;15(6):1331-6. PubMed PMID: 3058657. NO BRACHY 
52: Yeoh EK, Spittle MF. The treatment of carcinoma of the cervix and poor-risk 
endometrial carcinoma using the Cathetron at the Middlesex Hospital: experience 
since 1979. Clin Radiol. 1986 Mar;37(2):165-8. PubMed PMID: 3698502. CERVIX 
53: Battermann JJ, Tierie AH. Results of implantation for T1 and T2 bladder 
tumours. Radiother Oncol. 1986 Feb;5(2):85-90. PubMed PMID: 3085168. 
54: Shipley WU, Rose MA. Bladder cancer. The selection of patients for treatment  




55: Gérard JP, De Laroche G, Ardiet JM, Romestaing P, Auque JR. [Iridium 
curietherapy in conservative treatment of infiltrating cancer of the bladder]. J  
Urol (Paris). 1985;91(3):139-44. French. PubMed PMID: 4045208. FULL TEXT NOT IN 
ENGLISH 
56: Nag S, Blatnik A, Soloway M. Enhancement of high intensity Iodine-125 
brachytherapy by cis-platinum in a murine bladder tumor model. J Urol. 1984 
Jun;131(6):1225-8. PubMed PMID: 6539386. ANIMAL 
57: van der Werf-Messing B, Menon RS, Hop WC. Carcinoma of the urinary bladder 
category T3NxMo treated by the combination of radium implant and external 
irradiation: second report. Int J Radiat Oncol Biol Phys. 1983 Feb;9(2):177-80. 
PubMed PMID: 6833019. DUPLICATE 
58: Wijnmaalen A, Boeken Kruger CC. Organ preservation by external beam and 
afterloading interstitial radiation in patients with muscle infiltrating bladder  
cancer. Semin Urol Oncol. 2000 Nov;18(4):308-12. Review. PubMed PMID: 
11101095. REVIEW 
59: Moonen LM, Horenblas S, Pos F, Schaefer BS, Meinhardt W, Bartelink H. [Good 
results of bladder-preserving treatment in poorly differentiated and invasive 
bladder carcinoma using interstitial Iridium-192 radiotherapy]. Ned Tijdschr 
Geneeskd. 1996 Jul 6;140(27):1406-10. Dutch. PubMed PMID: 8766684. 
60: van der Werf-Messing B, Menon RS, Hop WC. Cancer of the urinary bladder 
category T2, T3, (NxMo) treated by interstitial radium implant: second report. 
Int J Radiat Oncol Biol Phys. 1983 Apr;9(4):481-5. PubMed PMID: 6853251. 
DUPLICATE 
 
 
